Status: current, Defined. Date: 28-Feb 2022. Module: SNOMED CT core
Descriptions:
Id | Description | Lang | Type | Status | Case? | Module |
4696218013 | Product containing precisely efavirenz 400 milligram and lamivudine 300 milligram and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Case insensitive | SNOMED CT core |
4696219017 | Efavirenz 400 mg and lamivudine 300 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | en | Synonym | Active | Case insensitive | SNOMED CT core |
Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
Efavirenz 400 mg and lamivudine 300 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | Is a | Efavirenz and lamivudine and tenofovir only product in oral dose form | true | Inferred relationship | Some | ||
Efavirenz 400 mg and lamivudine 300 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | Has manufactured dose form | Conventional release oral tablet | true | Inferred relationship | Some | ||
Efavirenz 400 mg and lamivudine 300 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | Has unit of presentation | Tablet | true | Inferred relationship | Some | ||
Efavirenz 400 mg and lamivudine 300 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | Plays role | Antiretroviral therapeutic role | true | Inferred relationship | Some | ||
Efavirenz 400 mg and lamivudine 300 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | Has precise active ingredient | Lamivudine | true | Inferred relationship | Some | 1 | |
Efavirenz 400 mg and lamivudine 300 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | Has BoSS | Lamivudine | true | Inferred relationship | Some | 1 | |
Efavirenz 400 mg and lamivudine 300 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 1 | |
Efavirenz 400 mg and lamivudine 300 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | Has presentation strength denominator unit | Tablet | true | Inferred relationship | Some | 1 | |
Efavirenz 400 mg and lamivudine 300 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | Has precise active ingredient | Efavirenz | true | Inferred relationship | Some | 2 | |
Efavirenz 400 mg and lamivudine 300 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | Has BoSS | Efavirenz | true | Inferred relationship | Some | 2 | |
Efavirenz 400 mg and lamivudine 300 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 2 | |
Efavirenz 400 mg and lamivudine 300 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | Has presentation strength denominator unit | Tablet | true | Inferred relationship | Some | 2 | |
Efavirenz 400 mg and lamivudine 300 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | Has precise active ingredient | Tenofovir disoproxil fumarate | true | Inferred relationship | Some | 3 | |
Efavirenz 400 mg and lamivudine 300 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | Has BoSS | Tenofovir disoproxil | true | Inferred relationship | Some | 3 | |
Efavirenz 400 mg and lamivudine 300 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 3 | |
Efavirenz 400 mg and lamivudine 300 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | Has presentation strength denominator unit | Tablet | true | Inferred relationship | Some | 3 |
Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets